Description

Basic Info.

B7-33 is a novel, synthetic compound that was first discovered and developed by a team of researchers at the Monash University in Australia. The development of B7-33 was based on the discovery of the relaxin receptor 1 (RXFP1) and the recognition of its potential as a therapeutic target for a wide range of diseases and conditions.

The research team, led by Professor David Handelsman, first synthesized B7-33 in the early 2010s as part of their efforts to develop a functionally selective agonist for RXFP1. This compound was then tested in a series of in vitro and in vivo studies, which demonstrated its potential as a treatment for hypertension, kidney disease, and heart failure. The team's research on B7-33 was published in several scientific journals, including the Journal of Biological Chemistry and the Journal of Hypertension. 

These publications highlighted the compound's unique mechanism of action and its potential as a treatment option for patients.

packing & Delivery

Product packaging

We have cooperated with experienced shipping forwarders for many years, they arrange the shipment. No matter by express, by air or by sea, we will track the course of the goods all the way, to make sure goods arrive at you on time and in good condition.

< Previous

Bronchogen (Bronchi)

Next >

Cardiogen(Myocardium)

Send A Message

We'd love to hear from you if you have any questions!

submit review submit review

Related Products

Hyaluronic acid

FG Loop(FGL)

HMG

snap-8